‘Next generation’ chromium shows superior insulin management
date:Jun 13, 2012
ficant reductions of about 30% in both fasting insulin levels and insulin resistance.

In addition, the chromium dinicocysteinate group also displayed significantly reduced levels of the inflammatory cytokine TNF-alpha (21%) and significantly reduced the oxidative stress marker protein carbonyl (10%).

On the other hand, the chromium picolinate group did not display significant changes in insulin levels, insulin resistance, TNF-alpha and protein carbonyl levels compared to baseline values, said
6/8 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
05/17 10:09